Revolution Medicines Inc (NASDAQ: RVMD) (FRA: 42Z) is taking the oncology field by storm. Its new pill targets a deadly cancer that has long defied effective treatment.
Last week, the firm secured FDA approval for Rasonque. The once-daily tablet treats adults with metastatic pancreatic cancer who have already tried other therapies or cannot handle strong combination chemotherapy. Shares rose about 2 per cent on the back of the news, a modest move after strong trial results had already lifted the stock sharply earlier this year. The medicine is now available in the United States at a hefty price of US$39,800 for a 30-day supply.
FDA approval has established it as the first broad treatment that hits the main driver of most pancreatic tumours. This approval came earlier than many expected. Rasonque works by blocking several forms of the rat sarcoma (RAS) protein. This protein acts like a switch that tells cancer cells to grow and spread. Pancreatic cancer is hard to treat because doctors often find it late, the disease grows fast, and older drugs give only limited help.
In the main study of roughly 500 patients, those who took Rasonque lived a median of 13.2 months compared with 6.7 months on standard chemotherapy. Though not a cure, the drug cut the risk of death by 60 per cent. Patients also stayed free of disease progression longer and kept a better quality of life. More than 2,000 people had already received the drug through an early-access scheme across almost every American state, and the benefit held steady across different patient groups.
“We are finally making progress against one of cancer researchers’ greatest challenges,” said Pancreatic Cancer Action Network Chief Medical Officer, Anna Berkenblit.
Despite enthusiasm, certain patients like former American senator Ben Sasse have reported severe side effects. Revolution says occurrences like these are rare.
Two months after the standing ovation, Revolution Medicines' RAS inhibitor is officially FDA-approved for metastatic pancreatic cancer. https://t.co/LDaSih98IC
— Samuel Hume (@DrSamuelBHume) August 26, 2026
Read more: Breath Diagnostics advances pre-op pneumonia screening with FDA breakthrough designation
The long road to approval
Getting here took more than a decade of research and heavy spending, and the firm is now ready to start seeing an ROI. The high price mainly reflects the strong survival benefit the drug delivers and the extensive process involved with creating it rather than manufacturing costs.
The considerable price tag will definitely challenge some patients. A full year of treatment carries a list cost of nearly US$480,000 — more than many houses. To mitigate this burden, the firm has launched its (ON)Path programme to help patients navigate insurance, secure financial assistance and access education about the treatment. Eligible commercially insured patients may pay as little as US$0 in co-pays.
Analysts expect strong early sales that could push the company toward profitability within a few years, but high running costs mean the path will not be instant. The stock’s performance now hinges on how quickly doctors adopt the pill and whether later trials open it for earlier use or other cancers. The minimal share rise after approval shows investors already priced in much of the good news.
A busy time for cancer advances
This milestone arrives amid a surge of major developments in oncology. In a related development, Propanc Biopharma Inc (NASDAQ: PPCB) just reported strong early results with its own pancreatic cancer candidate that slowed tumour growth by more than 90 per cent and more than doubled survival in animal models. This drug uses a different approach than Rasonque.
Moderna Inc‘s (NASDAQ: MRNA) (ETR: 0QF) personalised cancer vaccine also scored a major win in a late-stage melanoma trial this month, sending its shares soaring by around 177 per cent in a single day. Additionally, Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) (FRA: J7Z) gained approval for its intravenous infusion treatment Ziihera on Aug. 25, which is beneficial against certain stomach and oesophageal cancers.
This week in medicine
1. Revolution Medicines' daraxonrasib gets FDA-approved!
2. Moderna's personalized cancer vaccine succeeds in a phase 3 trial for melanoma
3. Nektar's Treg-boosting antibody treats eczema in a phase 2 trial
4. Researchers at the Universities of…
— Samuel Hume (@DrSamuelBHume) August 30, 2026
Read more: Prestigious medtech intelligence firm recognizes Breath Diagnostics for innovation
—————————————————————
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
